Novartis is trading at $161.42, up 3.42%, on October 29, 2026, after its October 27 Q3 report beat core EPS estimates and it raised its full-year core operating income outlook.
- Strong sales of Kisqali and other priority brands supported the improved guidance.
- Revenue slightly missed estimates, while a del-desiran impairment sharply reduced reported profit, leaving the earnings picture mixed.
- No separate October 29 announcement explaining the live move surfaced in the search.